Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CEO Sean Duffy sold 12,944 shares of Omada Health stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $19.22, for a total transaction of $248,783.68. Following the sale, the chief executive officer directly owned 382,594 shares of the company's stock, valued at $7,353,456.68. This represents a 3.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Omada Health Price Performance
Shares of Omada Health stock traded down $3.86 on Friday, hitting $15.09. 4,709,304 shares of the company's stock traded hands, compared to its average volume of 1,032,454. The firm's 50-day moving average price is $20.14 and its two-hundred day moving average price is $17.74. The stock has a market capitalization of $923.81 million, a PE ratio of 71.86 and a beta of 2.13. Omada Health, Inc. has a one year low of $10.28 and a one year high of $25.45.
Omada Health (NASDAQ:OMDA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. The business had revenue of $91.31 million for the quarter. On average, analysts forecast that Omada Health, Inc. will post 0.09 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Omada Health during the second quarter worth $48,775,000. Jefferies Financial Group Inc. acquired a new position in Omada Health in the 2nd quarter worth $15,016,000. Madryn Asset Management LP bought a new position in Omada Health during the 2nd quarter worth about $12,814,410. Walleye Capital LLC bought a new position in Omada Health during the 2nd quarter worth about $11,648,000. Finally, Renaissance Technologies LLC increased its holdings in Omada Health by 173.9% during the 1st quarter. Renaissance Technologies LLC now owns 391,069 shares of the company's stock worth $4,916,000 after purchasing an additional 248,269 shares in the last quarter.
Analysts Set New Price Targets
OMDA has been the topic of a number of analyst reports. Robert W. Baird increased their price target on shares of Omada Health from $15.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, August 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Omada Health in a research note on Friday, September 11th. Weiss Ratings lowered shares of Omada Health from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, October 8th. Wells Fargo & Company reduced their price target on shares of Omada Health from $22.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Omada Health from $26.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $26.33.
Get Our Latest Stock Report on Omada Health
Key Headlines Impacting Omada Health
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
- Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
- Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
- Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
- Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action
About Omada Health
(
Get Free Report)
Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.
The company's offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada's technology platform.
Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
